SEC Tracker
Get the app

Millendo Therapeutics TPST

Millendo Therapeutics appoints Louis J. Arcudi III as Chief Executive Officer

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
  • Announces exit or restructuring costs (2.05)
  • Reports an executive or board change (5.02)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Millendo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. ProMIS Neurosciences PMN public float $30M, Jun 30, 2025
  2. Provectus Biopharmaceuticals PVCT public float $31M, Jun 30, 2025
  3. Cumberland Pharmaceuticals CPIX public float $29M, Jun 30, 2025
  4. Rockwell Medical RMTI public float $29M, Jun 30, 2025
  5. Champions Oncology CSBR public float $29M, Oct 31, 2025